Because CSCs show tumor seeding ability and resistance to conventional therapies [16], we examined expression of established CSC markers such as CD44 and aldehyde dehydrogenase (ALDH) activity [17, 18] after CDDP treatment. The gene discussed is CD44; the disease is neoplasm.